[go: up one dir, main page]

PE20080103A1 - AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu - Google Patents

AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu

Info

Publication number
PE20080103A1
PE20080103A1 PE2007000664A PE2007000664A PE20080103A1 PE 20080103 A1 PE20080103 A1 PE 20080103A1 PE 2007000664 A PE2007000664 A PE 2007000664A PE 2007000664 A PE2007000664 A PE 2007000664A PE 20080103 A1 PE20080103 A1 PE 20080103A1
Authority
PE
Peru
Prior art keywords
alkyl
modulators
compounds
elongation factor
aminotizoles
Prior art date
Application number
PE2007000664A
Other languages
English (en)
Inventor
Matthew J Lamarche
Simon Bushell
Michael A Patane
Lewis Whitehead
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080103(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080103A1 publication Critical patent/PE20080103A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS AMINOTIAZOLES DE FORMULA (I) DONDE A ES UN ENLACE, H, CH2, C(O), S(O)2, ENTRE OTROS; G ESTA AUSENTE O ES H, CICLOALQUILO, ARILO, ENTRE OTROS; J ES H, F, O-ALQUILO, CO2H, P(O)(OH)2, ENTRE OTROS; R1 ES H, C(ALQUILO)2-J O R4b; R2a ES H, ALQUILO, OH, OR4a, ENTRE OTROS; R2b ESTA AUSENTE O ES H, ALQUILO, ENTRE OTROS; R3 Y R12 SON CADA UNO H, HALOGENO, OR4b, ENTRE OTROS; R4a ES H O ALQUILO; R4b ES ALQUILO O (CH2-CH2-O-)n-R9, DONDE n ES DE 1 A 500; R9 ES H, ALQUILO O CH2CO2H; R5 ES H, ALQUILO O R4b. SON COMPUESTOS PREFERIDOS LOS COMPUESTOS DE FORMULA (i), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL FACTOR DE ELONGACION EF-Tu SIENDO UTILES EN EL TRATAMIENTO DE INFECCIONES BACTERIANAS
PE2007000664A 2006-05-31 2007-05-29 AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu PE20080103A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80969306P 2006-05-31 2006-05-31

Publications (1)

Publication Number Publication Date
PE20080103A1 true PE20080103A1 (es) 2008-04-03

Family

ID=38645676

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000664A PE20080103A1 (es) 2006-05-31 2007-05-29 AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
PE2012000528A PE20121011A1 (es) 2006-05-31 2007-05-29 AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000528A PE20121011A1 (es) 2006-05-31 2007-05-29 AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu

Country Status (31)

Country Link
US (2) US7851439B2 (es)
EP (2) EP2322536A3 (es)
JP (1) JP5351014B2 (es)
KR (1) KR101061658B1 (es)
CN (2) CN101454337A (es)
AR (1) AR060977A1 (es)
AU (1) AU2007255025B2 (es)
BR (1) BRPI0711885A2 (es)
CA (1) CA2650133A1 (es)
CL (1) CL2007001542A1 (es)
CR (1) CR10430A (es)
DK (1) DK2044101T3 (es)
EC (1) ECSP088922A (es)
ES (1) ES2441993T3 (es)
HR (1) HRP20140055T1 (es)
IL (1) IL194880A (es)
MA (1) MA30485B1 (es)
MX (1) MX2008015216A (es)
MY (1) MY146920A (es)
NO (1) NO20085032L (es)
NZ (1) NZ572154A (es)
PE (2) PE20080103A1 (es)
PL (1) PL2044101T3 (es)
PT (1) PT2044101E (es)
RU (1) RU2450015C2 (es)
SI (1) SI2044101T1 (es)
TN (1) TNSN08496A1 (es)
TW (2) TW201107337A (es)
UA (1) UA95627C2 (es)
WO (1) WO2007142986A2 (es)
ZA (1) ZA200808449B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080103A1 (es) 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
EP2097423B1 (en) * 2006-12-20 2011-03-02 Novartis AG Aminothiazole macrocycles, their use as antibacterial compounds and processes for their production
WO2008148754A2 (en) 2007-06-04 2008-12-11 Novartis Ag Macrocycles and their uses
AU2012261611B2 (en) * 2007-12-12 2014-05-15 Novartis Ag Aminothiazoles and their uses
EA020205B1 (ru) * 2007-12-12 2014-09-30 Новартис Аг Аминотиазолы, фармацевтические композиции на их основе и способы лечения бактериальной инфекции
WO2014167371A1 (en) * 2013-04-12 2014-10-16 Naicons S.C.A.R.L. Analogs of the antibiotic aminothiazole ge2270
CN106366168B (zh) * 2016-08-26 2020-09-15 上海交通大学 羊毛硫肽类抗菌肽及其脱氢衍生物的制备方法
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN113219078B (zh) * 2021-03-25 2022-12-16 广东产品质量监督检验研究院（国家质量技术监督局广州电气安全检验所、广东省试验认证研究院、华安实验室） 一种生活用纸制品中17种有机抗菌剂快速筛查方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202241A (en) 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
DE69016284T2 (de) 1989-07-04 1995-05-24 Lepetit Spa Antibiotikum GE 22270, Faktoren A1,A2,A3 und H.
ATE121459T1 (de) 1990-03-08 1995-05-15 Lepetit Spa Antibiotika ge 2270 faktoren b1, b2, c1, d1, d2, e und t.
IL100572A (en) 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
DE69224497T2 (de) 1991-08-30 1998-07-02 Biosearch Italia Spa Faktor C2a des Antibiotikums CE 2270
US5882900A (en) * 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
JPH08504782A (ja) 1992-12-22 1996-05-21 グルポ・レペチツト・エス・ピー・エイ 抗生物質ｇｅ３７４６８ａ、ｂ及びｃ
AU3805295A (en) 1994-11-08 1996-05-31 Gruppo Lepetit S.P.A. Microbial transformation process for obtaining antibiotic ge 2270 factor d2
DE69600244T2 (de) 1995-02-07 1998-10-01 Biosearch Italia Spa Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika
AU693989B2 (en) 1995-02-07 1998-07-09 Vicuron Pharmaceuticals Inc. Basic oxazoline-amide derivatives of GE 2270 and GE 2270-like antibiotics
JP2000505438A (ja) * 1996-02-14 2000-05-09 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ 抗生物質ＧＥ２２７０因子Ｃ▲下２ａ▼、Ｄ▲下２▼およびＥの誘導体
JPH1059997A (ja) * 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
ATE509633T1 (de) 2002-06-17 2011-06-15 Naicons S C A R L Verwendung eines amid-derivats des ge 2270 faktors a3 für die behandlung von akne
CN101198318A (zh) 2004-09-22 2008-06-11 默克公司 抗生素化合物
PE20080103A1 (es) 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
EA020205B1 (ru) * 2007-12-12 2014-09-30 Новартис Аг Аминотиазолы, фармацевтические композиции на их основе и способы лечения бактериальной инфекции

Also Published As

Publication number Publication date
RU2450015C2 (ru) 2012-05-10
ECSP088922A (es) 2008-12-30
TWI342310B (en) 2011-05-21
MY146920A (en) 2012-10-15
CN102399260B (zh) 2015-04-15
IL194880A (en) 2015-02-26
EP2044101A2 (en) 2009-04-08
KR101061658B1 (ko) 2011-09-01
CN101454337A (zh) 2009-06-10
EP2044101B1 (en) 2013-10-09
CN102399260A (zh) 2012-04-04
WO2007142986A2 (en) 2007-12-13
TW201107337A (en) 2011-03-01
JP5351014B2 (ja) 2013-11-27
PT2044101E (pt) 2014-01-03
KR20090006869A (ko) 2009-01-15
NZ572154A (en) 2011-12-22
PL2044101T3 (pl) 2014-03-31
WO2007142986A3 (en) 2008-04-10
HK1127614A1 (en) 2009-10-02
PE20121011A1 (es) 2012-08-25
EP2322536A3 (en) 2011-11-30
JP2009538914A (ja) 2009-11-12
AU2007255025A1 (en) 2007-12-13
AU2007255025B2 (en) 2011-07-14
DK2044101T3 (da) 2014-01-13
BRPI0711885A2 (pt) 2012-03-06
CA2650133A1 (en) 2007-12-13
SI2044101T1 (sl) 2014-01-31
US20100267757A1 (en) 2010-10-21
ES2441993T3 (es) 2014-02-07
RU2008150785A (ru) 2010-07-10
TNSN08496A1 (en) 2010-04-14
MA30485B1 (fr) 2009-06-01
US20080221142A1 (en) 2008-09-11
MX2008015216A (es) 2008-12-12
UA95627C2 (ru) 2011-08-25
ZA200808449B (en) 2014-12-23
NO20085032L (no) 2008-12-16
CR10430A (es) 2009-01-15
IL194880A0 (en) 2011-08-01
AR060977A1 (es) 2008-07-23
HRP20140055T1 (hr) 2014-02-14
EP2322536A2 (en) 2011-05-18
CL2007001542A1 (es) 2008-03-14
US7851439B2 (en) 2010-12-14
TW200811189A (en) 2008-03-01

Similar Documents

Publication Publication Date Title
PE20080103A1 (es) AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PA8631901A1 (es) 4-fenillamino-quinazolin-6-il-amidas
PE20110547A1 (es) Compuestos de isoindolina con actividad anticancerigena
PE20081887A1 (es) Nuevo compuesto de adenina
PE20090772A1 (es) Derivados de bencimidazol
PE20120691A1 (es) Derivados de n1-sulfonil-5-fluoropirimidinona
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
SV2006002110A (es) Compuestos terapeuticos ref. pc32293a
PE20091237A1 (es) Derivados de pirrolidina como moduladores de serina proteasas
PE20110344A1 (es) Derivados de etanodiamida como inhibidores de la integrasa del vih
PE20080263A1 (es) Compuestos de pirrolo-pirimidina y sus usos
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20080070A1 (es) Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c
PE20120632A1 (es) Inhibidores de bace
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20090057A1 (es) Compuestos y composiciones como moduladores de la actividad gpr119
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.
UY28005A1 (es) Indol -3-carboxamidas como activadores de glucoquinasa (gk)
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
PE20071311A1 (es) Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal

Legal Events

Date Code Title Description
FC Refusal